PMID- 10073291
OWN - NLM
STAT- MEDLINE
DCOM- 19990430
LR  - 20201226
IS  - 0066-4219 (Print)
IS  - 0066-4219 (Linking)
VI  - 50
DP  - 1999
TI  - Dendritic cell vaccines for cancer immunotherapy.
PG  - 507-29
AB  - Human tumors express a number of protein antigens that can be recognized by T 
      cells, thus providing potential targets for cancer immunotherapy. Dendritic cells 
      (DCs) are rare leukocytes that are uniquely potent in their ability to present 
      antigens to T cells, and this property has prompted their recent application to 
      therapeutic cancer vaccines. Isolated DCs loaded with tumor antigen ex vivo and 
      administered as a cellular vaccine have been found to induce protective and 
      therapeutic anti-tumor immunity in experimental animals. In pilot clinical trials 
      of DC vaccination for patients with non-Hodgkin's lymphoma and melanoma, 
      induction of anti-tumor immune responses and tumor regressions have been 
      observed. Additional trials of DC vaccination for a variety of human cancers are 
      under way, and methods for targeting tumor antigens to DCs in vivo are also being 
      explored. Exploitation of the antigen-presenting properties of DCs thus offers 
      promise for the development of effective cancer immunotherapies.
FAU - Timmerman, J M
AU  - Timmerman JM
AD  - Department of Medicine, Stanford University School of Medicine, California 94305, 
      USA. jtimmer@leland.stanford.edu
FAU - Levy, R
AU  - Levy R
LA  - eng
GR  - CA33399/CA/NCI NIH HHS/United States
GR  - HL57443/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Annu Rev Med
JT  - Annual review of medicine
JID - 2985151R
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Vaccines)
SB  - IM
MH  - Animals
MH  - Antigen Presentation/immunology
MH  - Antigens, Neoplasm/immunology
MH  - Clinical Trials as Topic
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - *Immunotherapy
MH  - Immunotherapy, Adoptive
MH  - Lymphoma, Non-Hodgkin/therapy
MH  - Melanoma/therapy
MH  - Neoplasms/*therapy
MH  - Neoplasms, Experimental/therapy
MH  - Pilot Projects
MH  - Remission Induction
MH  - T-Lymphocytes/immunology
MH  - *Vaccines
RF  - 111
EDAT- 1999/03/12 00:00
MHDA- 1999/03/12 00:01
CRDT- 1999/03/12 00:00
PHST- 1999/03/12 00:00 [pubmed]
PHST- 1999/03/12 00:01 [medline]
PHST- 1999/03/12 00:00 [entrez]
AID - 10.1146/annurev.med.50.1.507 [doi]
PST - ppublish
SO  - Annu Rev Med. 1999;50:507-29. doi: 10.1146/annurev.med.50.1.507.